Contact

Alexander Egilman, BA

Our Team

Alexander Egilman, BA

Senior Research Assistant

Alexander Egilman is a Senior Research Assistant with PORTAL. His research focuses on laws, policies, and anticompetitive practices that affect patient access to affordable, safe, and innovative treatments. His work has appeared in JAMA, Annals of Internal Medicine, The BMJ, and The New York Times.

Egilman is a graduate of Haverford College.

Featured Work

Simple graphic of magnifying glass examining papers to signify reviewing research publications.

Added Therapeutic Benefit of Top-Selling Brand-Name Drugs in Medicare

Egilman AC, Rome BN, Kesselheim AS - JAMA

Research Publications

| April 2023

Price, Value, and Access
Regulation and Clinical Evidence

More than half of the top‑selling brand‑name drugs in Medicare provided little or no added therapeutic benefit compared with existing treatments, yet accounted for a large share of Medicare spending. These findings support using comparative effectiveness evidence in Medicare price negotiations.

View Source

Frequency of Approval and Marketing of Biosimilars with a Skinny Label and Associated Medicare Savings

Egilman AC, Van de Wiele VL, Rome BN, Darrow JJ, Tu SS, Kesselheim AS, Sarpatwari A - JAMA Internal Medicine

Research Publications

| January 2023

Innovation Incentives and Competition
Price, Value, and Access
Regulation and Clinical Evidence

Between 2015 and 2021, 67% of biosimilars were approved with skinny labels, enabling earlier competition before all patents expired on the originator biologic expired. This pathway generated an estimated $1.5 billion in Medicare savings, highlight the value of this pathway amid increasing legal threats.

View Source

Estimated Medicare Part B Savings From Inflationary Rebates

Egilman AC, Kesselheim AS, Rome BN - JAMA

Research Publications

| January 2023

Price, Value, and Access

If Medicare inflationary rebates had applied from 2018 to 2020, Medicare Part B drug spending would have been reduced by roughly 3%. The largest savings came from biologics and rare-disease drugs with prices rising faster than inflation.

View Source